NOVAMED INC Form 8-K October 31, 2007

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event October 31, 2007 reported):

NovaMed, Inc. (Exact Name of Registrant as Specified in Charter)

Delaware (State or Other Jurisdiction of incorporation) 0-26625 (Commission File Number) 36-4116193 (IRS Employer Identification No.)

980 North Michigan Avenue, Suite 1620, Chicago, Illinois60611(Address of Principal Executive Offices)(Zip Code)

Registrant's telephone number, including area code (312) 664-4100

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- o Written communications pursuant to Rule 425 under the Securities Act
- o Soliciting material pursuant to Rule 14a-12 under the Exchange Act
- o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
- O Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act

Section 2 - Financial Information

Item 2.02 Results of Operations and Financial Condition.

On October 31, 2007, NovaMed, Inc. issued a press release announcing its results of operations for the period ended September 30, 2007. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1.

The information in this Form 8-K and Exhibit 99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.

Section 9 - Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits

(c) Exhibits

E x h i b i t Title Number

99.1 Press release of NovaMed, Inc. dated October 31, 2007

Edgar Filing: NOVAMED INC - Form 8-K

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NovaMed, Inc.

Dated: October 31, 2007

By: /s/ Scott T. Macomber

Scott T. Macomber Executive Vice President and Chief Financial Officer

Edgar Filing: NOVAMED INC - Form 8-K

EXHIBIT INDEX

Exhibit No. Exhibit

99.1 Press release of NovaMed, Inc. dated October 31, 2007

: times new roman">\$9.75 \$7.20 \$3.84 James M. Feigley Director \$2.22

James K. Harlan Director

> 10,000 62,500 50,000 50,000 50,000

10,000

-3-

\$2.96 \$4.25 \$5.76 \$7.20 \$8.40

David C. Hurley Director	10,000 100,000 50,000 75,000 50,000	\$2.96 \$4.25 \$5.76 \$7.20 \$8.40
James A. McDivitt	10,000 50,000 50,000 150,000	\$2.96 \$4.25 \$7.20 \$9.75

Included in the new options granted on March 9, 2009 were options to purchase: (i) 100,000 shares to Mr. Marshall, (ii) 210,000 shares to Mr. Wallace, (iii) 5,000 shares to Mr. Feigley, (iv) 111,250 shares to Mr. Harlan, (v) 142,500 shares to Mr. Hurley and (vi) 130,000 shares to Mr. McDivitt.

Item 12 of the Schedule TO is amended to refer to a new Exhibit (a)(11), a copy of which is filed with this Amendment to Schedule TO.

Item 12. Exhibits

(a)(11)Form of email communication dated March 9, 2009 to option holders who changed options in the Company's Offer to Exchange Certain Options.

SIGNATURE

After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

APPLIED ENERGETICS, INC.

/s/ Kenneth M. Wallace Kenneth M. Wallace Chief Financial Officer

Date: March 10, 2009

-5-

INDEX TO EXHIBITS

Exhibit NumberDescription(a)(11)Form of email communication dated March 9, 2009 to option holders who
exchanged options in the company's offer to exchange certain